The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO
Haifaa Abdulhaq, MD, University of California San Francisco, San Francisco, CA, discusses a subgroup analysis from the STARGLO study (NCT04408638), which evaluated the efficacy of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab (R)-GemOx in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Abdulhaq reports improved responses in the glofitamab-GemOx arm. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This was a subgroup analysis from the STARGLO study, which was a Phase III randomized trial that evaluated patients with relapsed/refractory diffuse large B-cell lymphoma who are transplant-ineligible. These patients were randomized to receive either glofitamab-GemOx or R-GemOx. Patients who had glofitamab-GemOx received eight cycles of the treatment and then received glofitamab monotherapy for four more cycles...
This was a subgroup analysis from the STARGLO study, which was a Phase III randomized trial that evaluated patients with relapsed/refractory diffuse large B-cell lymphoma who are transplant-ineligible. These patients were randomized to receive either glofitamab-GemOx or R-GemOx. Patients who had glofitamab-GemOx received eight cycles of the treatment and then received glofitamab monotherapy for four more cycles. And patients on the R-GemOx arm had eight cycles of chemotherapy. This particular paper focused on the subgroup analysis at 36 months of follow-up, looking at patients paired by their age group as well as the line of therapy. And what we do see from the subgroup analysis is there was sustained benefit of glofitamab-GemOx versus R-GemOx in all age groups, patients who are less than 65, more than 65, and also more than 75 years of age. What was noticeable to me is particularly in the patients who were more than 75 years of age, they had a median overall survival of 33 months and their complete response rates was about 65%. When we look at the lines of therapy, there was a benefit of glofitamab-GemOx over R-GemOx in both patients who were treated in second line as well as third line and beyond. However, there was particularly more pronounced benefit in the patients who were treated in the second line. Then when we looked at the patients in the second line who had early relapse versus late relapse, there was also benefit of the glofitamab-GemOx versus R-GemOx in both patient subgroups. So though I would say in early relapse patients, it was even more impressive in those patients in terms of their complete response rate as well as median overall survival. So as far as the safety profile, there were no additional safety signals. We did see in patients more than 75 years of age. We did see some higher rates of infections as well as CRS. The CRS, the cytokine release syndrome, was about 55%. However, it was mostly grade one and two.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
